Evaluation of scar revision after inadequate primary excision of cutaneous mast cell tumors in 85 dogs (2000–2013)

Karbe, Georga; Davis, Elizabeth A.; Runge, Jeffrey J.; Brown, Dorothy Cimino; Holt, David E.

doi:10.1111/vsu.13619

Cited by 8 publications

(11 citation statements)

References 29 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of the technique used, it is necessary to avoid excessive manipulation of the lesion, seeking to avoid stimulation of mast cell degranulation and its consequent adverse effects [ 159 ]. In cases of tumor recurrence after initial excision, the main associated factor tends to be histological grading, with low recurrence rates after excision of grade 1 or II MCTs [ 160 , 161 ].…”

Section: Therapeutic Approachmentioning

confidence: 99%

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Nardi

Horta

Fonseca-Alves

et al. 2022

Cells

View full text Add to dashboard Cite

Mast cell tumors (MCTs) are hematopoietic neoplasms composed of mast cells. It is highly common in dogs and is extremely important in the veterinary oncology field. It represents the third most common tumor subtype, and is the most common malignant skin tumor in dogs, corresponding to 11% of skin cancer cases. The objective of this critical review was to present the report of the 2nd Consensus meeting on the Diagnosis, Prognosis, and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors, which was organized by the Brazilian Association of Veterinary Oncology (ABROVET) in August 2021. The most recent information on cutaneous and subcutaneous mast cell tumors in dogs is presented and discussed.

show abstract

Section: Therapeutic Approachmentioning

confidence: 99%

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Nardi

Horta

Fonseca-Alves

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…It is consistently reported that complete surgical resection is the treatment of choice for mast cell tumors, and complete histologic margins may be considered curative for lowgrade tumors [1,22,38,[41][42][43][44]47,50,51,53,54,[59][60][61]64,65,[70][71][72][73][74]83,[87][88][89][90][91][92][93][94][95][96][97][98]. Mast cell tumors can be deemed non-resectable or not amenable to curative-intent surgical margins.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis and subsequent management of the patient after definitive local therapy is dichotomized by the MCT grade. Typically, low-grade tumors require no further treatment, even if incompletely excised, and patients are expected to have good to excellent outcomes, while patients with high-grade tumors are expected to succumb to their disease and require intensive multi-modal therapeutic strategies [1,2,6,[35][36][37][38][39]48,[52][53][54][59][60][61][62][63][64][65][66][67]. This then raises the question of how preoperative glucocorticoid treatment may impact the histological parameters and criteria for grade determination and the immunohistochemical detection of proliferation indices in canine MCTs.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study

Klahn

Dervisis

Lahmers

et al. 2022

Veterinary Sciences

View full text Add to dashboard Cite

Glucocorticoid administration is a common clinical practice that attempts to decrease the inflammation associated with and improve the resectability of canine mast cell tumors (MCTs). However, the impact of neoadjuvant glucocorticoids on the histological features and proliferation indices of canine MCTs is unknown. The objective of this study was to evaluate changes in tumor grade, mitotic count, Ki67, AgNOR, and AgNORxKi67 scores following short-course anti-inflammatory neoadjuvant prednisone in canine patients with MCTs. This was a prospective single-arm pilot study. Client-owned dogs with treatment-naïve cytologically confirmed MCTs were enrolled. Patients underwent an initial incisional biopsy followed by a 10–14-day course of anti-inflammatory prednisone and surgical resection. All histological samples were randomized, masked, and evaluated by a single pathologist. Unstained paired pre- and post-treatment samples were submitted to a commercial laboratory for Ki67 and AgNOR immunohistochemical analysis. There were 11 dogs enrolled with 11 tumors. There were no statistical differences between the pre- and post-treatment histological parameters of mitotic index, Ki67, AgNOR, or Ki67xAgNOR. There were no clinically significant alterations between pre-treatment and post-treatment in the assignment of tumor grades. A short course of anti-inflammatory prednisone does not appear to alter the histological parameters that affect grade determination or significantly alter the proliferation indices in canine MCTs.

show abstract

“…It is consistently reported that complete surgical resection is the treatment of choice for mast cell tumors, and complete histologic margins may be considered curative for low-grade tumors [1,22,[41][42][43][44]47,50,51,55,60,62,63,66,67,[71][72][73][74][75]84,86,[89][90][91][92][93][94][95][96][97][98][99][100][101][102]. Mast cell tumors can be deemed non-resectable or not amenable to curative-intent surgical margins.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis and subsequent management of the patient after definitive local therapy is dichotomized by MCT grade. Typically, low-grade tumors require no further treatment, even if incompletely-excised, and patients are expected to have good to excellent outcomes; while patients with high-grade tumors are expected to succumb to their disease and require intensive multi-modal therapeutic strategies [1,2,6,[35][36][37][38][39]48,52,55,[60][61][62][63][64][65][66][67][68][69]. This then raises the question of how pre-operative glucocorticoid treatment may impact histological parameters, criteria for grade determination and immunohistochemical detection of proliferation indices in canine MCTs.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors

Klahn¹,

Dervisis²,

Lahmers³

et al. 2022

Preprint

View full text Add to dashboard Cite

Glucocorticoid administration is a common clinical practice in attempt to decrease inflammation associated with, and improve resectability of, canine mast cell tumors (MCTs). However, the impact of neoadjuvant glucocorticoids on histological features and proliferation indices of canine MCTs is unknown. The objective of this study was to evaluate changes in tumor grade, mitotic count, Ki67, AgNOR, and AgNORxKi67 scores following short-course, anti-inflammatory neoadjuvant prednisone in canine patients with MCTs. This was a prospective, single-arm pilot study. Client-owned dogs with treatment-naïve, cytologically-confirmed MCTs were enrolled. Patients underwent an initial incisional biopsy followed by a 10-14 day course of anti-inflammatory prednisone, and surgical resection. All histological samples were randomized, masked, and evaluated by a single pathologist. Unstained paired pre- and post-treatment samples were submitted to a commercial laboratory for Ki67 and AgNOR immunohistochemical analysis. There were 11 dogs enrolled with 11 tumors. There were no statistical differences between the pre- and post-treatment histological parameters of mitotic index, Ki67, AgNOR, or Ki67xAgNOR. There were no clinically-significant alterations between pre-treatment and post-treatment in the assignment of tumor grades. A short-course of anti-inflammatory prednisone does not appear to alter the histological parameters that affect grade-determination, nor significantly alter the proliferation indices in canine MCTs.

show abstract

Evaluation of scar revision after inadequate primary excision of cutaneous mast cell tumors in 85 dogs (2000–2013)

Abstract: Objective: To determine the frequency of residual tumor, and factors associated with local recurrence and disease progression in dogs with incompletely excised mast cell tumors (MCT) following scar revision surgery.

Cited by 8 publications

References 29 publications

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study

Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors

Contact Info

Product

Resources

About